PFS and OS analysis of patients with early HL
| . | Univariate analysis . | |||
|---|---|---|---|---|
| 5-year PFS (95% CI) . | P . | 5-year OS (95% CI) . | P . | |
| Age, y | .37 | .21 | ||
| 0-49 | 82% (74-89) | 90% (85-96) | ||
| ≥ 50 | 78% (61-95) | 87% (74-100) | ||
| Sex | .74 | .71 | ||
| Male | 81% (73-90) | 90% (82-97) | ||
| Female | 80% (69-92) | 90% (85-95) | ||
| Bulky mass | .25 | .79 | ||
| Yes | 73% (59-87) | 86% (75-98) | ||
| No | 84% (76-92) | 91% (85-97) | ||
| B symptoms | .021 | .003 | ||
| No | 88% (81-95) | 94% (89-99) | ||
| Yes | 66% (50-82) | 80% (67-93) | ||
| ECOG PS | .052 | .001 | ||
| 0-1 | 74% (67-80) | 92% (87-97) | ||
| 2-4 | 56% (17-95) | 47% (2-91) | ||
| ESR* | .15 | .02 | ||
| Normal | 75% (53-96) | 94% (84-100) | ||
| Elevated | 88% (73-100) | 82% (63-100) | ||
| Lymph node areas | .18 | .68 | ||
| 0-3 | 86% (75-97) | 89% (79-99) | ||
| ≥ 4 | 50% (0-100) | 50% (0-100) | ||
| EORTC score | .084 | .054 | ||
| Favorable | 91% (74-100) | 100% | ||
| Unfavorable | 74% (63-85) | 84% (75-93) | ||
| Type of treatment | .16 | .97 | ||
| 2-4 cycles | 84% (75-94) | 89% (81-97) | ||
| 6-8 cycles | 79% (69-88) | 91% (83-98) | ||
| RT | .007 | .11 | ||
| Yes | 86% (79-93) | 93% (88-99) | ||
| No | 72% (59-85) | 82% (69-95) | ||
| COX2 stain on RS | .017 | .004 | ||
| Positive | 72% (58-86) | 82% (71-83) | ||
| Negative | 86% (79-83) | 94% (88-99) | ||
| . | Univariate analysis . | |||
|---|---|---|---|---|
| 5-year PFS (95% CI) . | P . | 5-year OS (95% CI) . | P . | |
| Age, y | .37 | .21 | ||
| 0-49 | 82% (74-89) | 90% (85-96) | ||
| ≥ 50 | 78% (61-95) | 87% (74-100) | ||
| Sex | .74 | .71 | ||
| Male | 81% (73-90) | 90% (82-97) | ||
| Female | 80% (69-92) | 90% (85-95) | ||
| Bulky mass | .25 | .79 | ||
| Yes | 73% (59-87) | 86% (75-98) | ||
| No | 84% (76-92) | 91% (85-97) | ||
| B symptoms | .021 | .003 | ||
| No | 88% (81-95) | 94% (89-99) | ||
| Yes | 66% (50-82) | 80% (67-93) | ||
| ECOG PS | .052 | .001 | ||
| 0-1 | 74% (67-80) | 92% (87-97) | ||
| 2-4 | 56% (17-95) | 47% (2-91) | ||
| ESR* | .15 | .02 | ||
| Normal | 75% (53-96) | 94% (84-100) | ||
| Elevated | 88% (73-100) | 82% (63-100) | ||
| Lymph node areas | .18 | .68 | ||
| 0-3 | 86% (75-97) | 89% (79-99) | ||
| ≥ 4 | 50% (0-100) | 50% (0-100) | ||
| EORTC score | .084 | .054 | ||
| Favorable | 91% (74-100) | 100% | ||
| Unfavorable | 74% (63-85) | 84% (75-93) | ||
| Type of treatment | .16 | .97 | ||
| 2-4 cycles | 84% (75-94) | 89% (81-97) | ||
| 6-8 cycles | 79% (69-88) | 91% (83-98) | ||
| RT | .007 | .11 | ||
| Yes | 86% (79-93) | 93% (88-99) | ||
| No | 72% (59-85) | 82% (69-95) | ||
| COX2 stain on RS | .017 | .004 | ||
| Positive | 72% (58-86) | 82% (71-83) | ||
| Negative | 86% (79-83) | 94% (88-99) | ||
| . | Multivariate analysis . | |||
|---|---|---|---|---|
| PFS . | OS . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| COX2+ stain on RS | 2.76 (1.29-5.90) | .009 | 4.81 (1.60-14.44) | .005 |
| B symptoms | 2.34 (1.11-4.94) | .026 | — | — |
| RT | 0.32 (0.14-0.69) | .004 | — | — |
| ECOG PS > 1 | — | — | 9.00 (2.37-34.22) | .001 |
| . | Multivariate analysis . | |||
|---|---|---|---|---|
| PFS . | OS . | |||
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| COX2+ stain on RS | 2.76 (1.29-5.90) | .009 | 4.81 (1.60-14.44) | .005 |
| B symptoms | 2.34 (1.11-4.94) | .026 | — | — |
| RT | 0.32 (0.14-0.69) | .004 | — | — |
| ECOG PS > 1 | — | — | 9.00 (2.37-34.22) | .001 |
— indicates not significant.
Criteria for elevated erythrocyte sedimentation rate (ESR) were ≥ 50 if no B symptoms and ≥ 30 if B symptoms present.